Breakdown | |||||
TTM | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 | Sep 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
3.79M | 3.43M | 13.37M | 18.17M | 9.03M | 1.93M | Gross Profit |
1.55M | 1.02M | 5.53M | 5.05M | 4.93M | 1.21M | EBIT |
-13.04M | -14.02M | -10.95M | -13.97M | -12.29M | -12.53M | EBITDA |
-12.77M | -13.33M | -9.59M | -12.68M | -11.68M | -12.25M | Net Income Common Stockholders |
-31.28M | -6.99M | -9.95M | -8.38M | -16.03M | -12.76M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
6.82M | 6.43M | 7.15M | 15.22M | 6.55M | 7.79M | Total Assets |
13.04M | 12.79M | 13.65M | 22.27M | 14.42M | 11.34M | Total Debt |
472.39K | 739.16K | 1.24M | 0.00 | 0.00 | 2.35M | Net Debt |
-6.35M | -5.69M | -5.91M | -15.22M | -6.55M | -5.44M | Total Liabilities |
2.81M | 3.82M | 8.78M | 9.36M | 3.30M | 5.63M | Stockholders Equity |
10.22M | 9.14M | 4.95M | 12.91M | 11.11M | 5.72M |
Cash Flow | Free Cash Flow | ||||
-13.95M | -14.12M | -6.30M | -9.47M | -15.94M | -12.21M | Operating Cash Flow |
-13.25M | -13.71M | -6.22M | -8.98M | -13.39M | -11.14M | Investing Cash Flow |
-695.27K | -407.90K | -1.10M | -489.55K | -2.55M | -1.06M | Financing Cash Flow |
17.62M | 13.40M | 0.00 | 18.13M | 14.70M | 19.43M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
65 Neutral | $16.06M | ― | -25.29% | ― | 26.67% | 44.02% | |
59 Neutral | $11.06M | ― | -126.34% | ― | 3.87% | 91.76% | |
53 Neutral | $5.25B | 3.24 | -45.38% | 2.81% | 16.79% | -0.06% | |
42 Neutral | $3.03M | ― | -141.39% | ― | -58.46% | 47.98% | |
40 Neutral | $3.18M | ― | -265.37% | ― | -13.05% | 49.76% | |
34 Underperform | $2.57M | ― | -358.41% | ― | ― | 71.89% | |
$6.20M | ― | -24.75% | ― | ― | ― |
On September 30, 2024, Applied DNA Sciences’ stockholders approved a reverse stock split to address non-compliance with Nasdaq’s minimum bid price requirements. Effective March 14, 2025, the 1-for-50 reverse stock split aims to reduce the number of outstanding shares from approximately 55.2 million to 1.1 million, helping the company regain compliance and maintain its Nasdaq listing.